On Thursday, Shares of Goldcorp Inc. (USA) (NYSE:GG), gained 0.35% to $11.56.
On Tuesday, December 29, 2015, Nasdaq Composite ended at 5,107.94, up 1.33%, Dow Jones Industrial Average advanced 1.10% to finish the day at 17,720.98, and the S&P 500 closed at 2,078.36, up 1.06%.
Goldcorp Inc.’s stock slipped by 0.42% to close Tuesday’s session at USD 11.74. The company’s shares oscillated between USD 11.61 and USD 12.00. The stock recorded a trading volume of 5.39 million shares, which was below its 50-day daily average volume of 8.62 million shares and its 52-week average volume of 9.12 million shares. Over the last five days Goldcorp Inc.’s shares have declined by 0.59% and in the past one month the stock has lost 0.09%. In addition, over the last three months the stock has lost 3.85% and year to date the shares have shed 34.18%. The company has returned 1.83% in the past one month, on a compounded total return basis. Goldcorp Inc. has a current dividend yield of 1.97%. The stock is trading at a price to book ratio of 0.59, which compares to a historical PB ratio near to 0.89. Additionally, the stock is trading at a price to cash flow ratio of 9.90 and at a price to sales ratio of 2.65.
Goldcorp Inc. engages in the acquisition, exploration, development, and operation of precious metal properties in Canada, the United States, Mexico, and Central and South America. The company primarily explores for gold, silver, copper, lead, and zinc deposits.
Shares of Pluristem Therapeutics Inc. (NASDAQ:PSTI), inclined 14.14% to $1.13, during its last trading session.
Pluristem Therapeutics declared that the U.S. Food and Drug Administration have granted the Company’s PLX-PAD cells Orphan Drug Designation in the treatment of severe preeclampsia. Preeclampsia is among the most common medical complications of pregnancy and a leading cause of premature births, stillbirths and neonatal and maternal deaths. There is no cure except delivery. Due to high risks to the mother, women diagnosed with severe preeclampsia are usually delivered promptly, even if the baby will be born prematurely and may suffer permanent disabilities as a result. Severe preeclampsia occurs in about 1% of pregnancies in Western countries.
Benefits of Orphan Drug Designation for PLX-PAD cells comprise close guidance that may accelerate time to marketing approval, orphan drug grants, tax credits, and a 7-year market exclusivity upon marketing approval. It is estimated by different sources that preeclampsia costs the global health care system about $3 billion annually.
“Attainment of Orphan Drug Designation for our cells in severe preeclampsia exemplifies our global strategy of bringing cell therapies to patients through accelerated approval pathways,” stated Pluristem Chairman and CEO Zami Aberman. “We are encouraged by the US FDA designation that demonstrates Pluristem’s commitment to the program and the potential promise it holds to address a serious, unmet medical need faced by pregnant women every year.”
Pluristem Therapeutics Inc., through its partner, Pluristem Ltd., operates as a bio-therapeutics company in Israel. The company focuses on the research, development, clinical trial, and manufacture of cell therapeutics products and related technologies for the treatment of various ischemic and inflammatory conditions.
Finally, Staples, Inc. (NASDAQ:SPLS), ended its last trade with -0.63% loss, and closed at $9.47.
Staples, Inc. (SPLS) kicks off the New Year with the new back-to-business 110% Price Match Guarantee, giving customers even more confidence in Staples’ commitment to offer the best prices on products in stores and online. Staples is also assisting small business owners get more for less with the Business Less List, which offers the lowest prices on 28 essentials that businesses use the most every day.
“The New Year is a crucial time for business owners, and Staples is assisting our small business customers make more happen with a broad assortment of products at the lowest prices, expanded business services and easy ways to shop,” said Alison Corcoran, senior vice president of North American stores and online marketing, Staples. “At Staples, we have 30 years of experience assisting small businesses succeed, and we’re thrilled to build on that history with the back-to-business 110% Price Match Guarantee and Business Less List.”
To coincide with the back-to-business season – a time when small business owners are preparing for the year to come – Staples will price match items sold and shipped by Amazon.com, or any retailer that sells products in retail stores and online under the same brand. As part of the 110% Price Match Guarantee, customers will receive an additional 10 percent off the difference between the Staples price and the competitor price.
Staples, Inc., together with its auxiliaries, operates office products superstores. It operates through three segments: North American Stores & Online, North American Commercial, and International Operations. The company offers a range of office supplies, business technology products and services, facility and breakroom supplies, computers and mobility products, and office furniture under the Staples, Quill, and other proprietary brands.
